ReviewHematology. American Society of Hematology. Education Program2020
Challenges in chronic transfusion for patients with thalassemia.
Review in Hematology. American Society of Hematology. Education Program, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Guideline for transfusion management in Chinese children with transfusion-dependent thalassemia (2025)].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Guideline
- Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent β-thalassemia: results from Thal-Thalido study.Scientific reports · 2023Trial
- Production of Induced Pluripotent Stem Cell-Derived Red Blood Cells.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Consent for transfusion: global practices, documentation and patient understanding - a scoping review protocol.BMJ open · 2025Article
- Prospective Assessment of Cardiac Iron Deposition, Morphology, and Function by Magnetic Resonance Imaging in Non-Transfusion-Dependent and Neo-Transfusion-Dependent Thalassemia.Journal of clinical medicine · 2025Article
- The diagnosis of GH deficiency in adult β-thalassemic patients: are two different stimulation tests necessary to improve specificity?Pituitary · 2025Article
- Prediction of JENU-Negative Phenotype by Genotyping among Thai Patients with Multiple Transfusions.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025Article
- Real Life Blood Management Practices in Thalassemia and Myelodysplastic Syndrome Patients.Anemia · 2025Article
- Article
- Impact of met-haemoglobin and oxidative stress on endothelial function in patients with transfusion dependent β-thalassemia.Scientific reports · 2024Article
- Hearing Loss in Beta-Thalassemia: Systematic Review.Journal of clinical medicine · 2021Review
- The transfusion management of beta thalassemia in the United States.Transfusion · 2021Review
- Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing.International journal of molecular sciences · 2021Review
- Deformability of Stored Red Blood Cells.Frontiers in physiology · 2021Review
- Delayed hemolytic transfusion reaction associated with anti-AuBlood transfusion = Trasfusione del sangueArticle
- Assessing RBC transfusion efficacy in chronic transfusion recipients: advancing precision transfusion medicine.Blood transfusion = Trasfusione del sangueArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of regular red cell transfusions 60 years ago transformed β-thalassemia major from a fatal childhood illness into a chronic disorder. Further advances in the prevention of transfusion-transmitted infections and management of iron overload have allowed survival and quality of life to approach normal. However, transfusion therapy for some other thalassemia syndromes continues to challenge clinical decision-making. Nearly one-half of the patients with E ß thalassemia are transfusion-dependent, yet the criteria for initiating transfusions or hemoglobin targets are not well defined. Patients with thalassemia intermedia who begin transfusions as adults are at very high risk for developing red cell alloimmunization and serious hemolytic transfusion reactions. In the growing number of survivors of Bart hydrops fetalis, the approach to transfusion therapy and iron chelation is rapidly evolving. A collaboration between hematology and transfusion medicine specialists will be essential to improving patient care and developing evidence-based guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.